Goldman Sachs initiates coverage on Glaukos stock with Buy rating

Goldman Sachs initiated coverage on Glaukos (GKOS) with a Buy rating and a $103 price target, citing the company's strategic transformation into a hybrid device and ophthalmic pharmaceutical firm, its strong revenue growth profile, and the anticipated, underappreciated commercialization success of its iDose product. This positive assessment follows Glaukos's Q2 2025 earnings beat, driven by $31 million in U.S. iDose sales, though some analysts maintain a mixed outlook due to potential growth concerns in its corneal health business.

Analysis

Goldman Sachs has initiated coverage on Glaukos Corporation (GKOS) with a Buy rating and a $103 price target, underscoring a significant strategic pivot from a medical device pure-play to a hybrid device and ophthalmic pharmaceutical company. This positive outlook is supported by strong fundamentals, including 26.7% revenue growth over the last twelve months and a robust gross profit margin of 76.34%. The firm's confidence is primarily anchored in the anticipated commercial success of the iDose product, which Goldman believes is underappreciated by the market and contributes approximately $10 per share to its valuation. This thesis finds early validation in Glaukos's second-quarter 2025 results, where the company surpassed both revenue and EPS forecasts, reporting $124.1 million and -$0.24, respectively. Critically, this earnings beat was driven by $31 million in U.S. iDose sales, which successfully counterbalanced headwinds from reimbursement changes affecting other business segments. While other analysts at Piper Sandler and Stifel share this bullish sentiment with price targets of $165 and $115, Mizuho's recent price target reduction to $130 from $150 highlights a mixed outlook, specifically citing growth concerns in the company's corneal health business.

Key Decisions for Investors

• Investors should view the successful early commercialization of iDose, generating $31 million in Q2 sales, as a key validation of the company's growth thesis and justification for the bullish analyst sentiment led by Goldman Sachs.
• It is crucial to monitor the performance of the legacy business, particularly the corneal health segment, and any further news on reimbursement, as these factors represent the primary risk cited by analysts and have already demonstrated an ability to offset growth in other areas.
• Considering the wide dispersion in analyst price targets, from $103 to $165, portfolio managers should assess their own conviction on the long-term market penetration of iDose versus the persistent risks in the company's other segments when determining an appropriate entry point or position size.